CADScor®System

An innovative first-line diagnostic aid to rule out significant Coronary Artery Disease

CADScor®System

An innovative first-line diagnostic aid to rule out significant Coronary Artery Disease

CADScor®System

An innovative first-line diagnostic aid to rule out significant Coronary Artery Disease

A simple test to put a patient's mind at rest

The CADScor®System is an innovative, ultrasensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant CAD at the very first stage of the diagnostic pathway. The user-friendly test records and analyses the heart sounds of the patient and can be conducted by all trained healthcare professionals.

An easy solution to bring down costs, risk and stress

Founded image placeholder
Non-invasive, point-of-care-test reducing waiting time and stress for patients
Founded image placeholder
User-friendly, accurate and reliable rule-out diagnostic aid to be used prior to other testing
Founded image placeholder
Cost-effective and safe diagnostic aid displaying immediate results

See how the CADScor®System works

Based on acoustic technology, the CADScor®System records the heart sounds of the resting patient to analyze the myocardial movement and blood flow in the coronary arteries. The recording detects heart sound abnormalities, such as coronary murmurs correlated to coronary stenosis and stiffness. In less than ten minutes, the result is shown as a calculated CAD-score from 0-99, categorizing patients into two risk groups.

“The CADScor®System gives you peace of mind in just 10 minutes”

For investors

Acarix is a medical technology company marketing the CADScor®System, currently available in the USA, Sweden, Denmark, Finland, Germany, Austria, Switzerland, and the UK. The CADScor®System is developed from pioneering research on phonocardiography, providing an innovative, non-invasive and ultra-sensitive analytical diagnostic aid for immediate rule-out. The cost-effective and simple test has the potential to reduce the waiting time and stress for patients experiencing symptoms of CAD. Since 2016, Acarix is listed on Nasdaq First North Growth Market.

Updates